Safety Trolls?: Generic Firms Seek To Invalidate Xyrem REMS Patent Via PTO
This article was originally published in The Pink Sheet Daily
In a first by drug makers seeking covered business method patent review, Amneal, Par and Roxane petition PTO appeal board to cancel patent claims covering distribution of Jazz’s Xyrem.
You may also be interested in...
FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.